Development of a Model for Chemical Screening Based on Collateral Sensitivity to Target BTK C481S Mutant

Targeted therapies have improved the outcome of cancer, but their efficacy is intrinsically limited by the emergence of subclones with a mutation in the gene encoding the target protein. A few examples of collateral sensitivity have demonstrated that the conformational changes induced by these mutat...

Descripción completa

Detalles Bibliográficos
Autores principales: Libre, Camille, Moro-Sibilot, Ludovic, Giraud, Stéphane, Martin, Laetitia, Verhoeyen, Els, Costa, Caroline, Chebel, Amel, Bissay, Nathalie, Salles, Gilles, Genestier, Laurent, Sujobert, Pierre
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7226254/
https://www.ncbi.nlm.nih.gov/pubmed/32272741
http://dx.doi.org/10.3390/cancers12040901

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7226254/
https://www.ncbi.nlm.nih.gov/pubmed/32272741
http://dx.doi.org/10.3390/cancers12040901

Ejemplares similares